The Journal of the American College of Cardiology (JACC) publishes results from three European centers of clinical studies using CryoCath’s Arctic Front. This appearance in JACC further familiarizes U.S. physicians with the growing body of evidence in favor of the use of Arctic Front to treat paroxysmal atrial fibrillation.

CryoCath introduces its lead product, Arctic Front, to three new European markets: Italy, Belgium, and Spain.

CryoCath introduces its lead product, Arctic Front, to an important new market in Asia: Hong Kong.

CryoCath reports positive 6-month follow-up data from the feasibility stage of its U.S. Investigational Device (IDE) STOP AF trial with its Arctic Front® catheter

CryoCath appoints new President and CEO, Jan Keltjens

CryoCath treats first patient in the U.S. with the new SurgiFrost® XL, a minimally invasive probe for treating cardiac arrhythmias in stand-alone procedures

CryoCath secures FDA 510(k) clearance for SurgiFrost® XL, a new minimally invasive surgical probe for the treatment of cardiac arrhythmias

CryoCath presents a 12-month update on its pivotal Investigational Device (IDE) STOP AF trial

CryoCath receives FDA notification allowing the company to extend its pivotal Investigational Device (IDE) STOP AF trial by enrolling up to 150 patients in up to 20 centers

CryoCath treats first U.S. patient in pivotal Investigational Device (IDE) STOP AF trial

CryoCath launches FrostByte™ globally. This surgical clamp secures the contact point between the cryoablation probe segment and the cardiac tissue

CryoCath announces positive 12-month data for Arctic Front for the treatment of atrial fibrillation in a clinical trial in Germany

Following FDA approval, CryoCath launches U.S. pivotal Investigational Device (IDE) STOP AF trial to test the effectiveness of Arctic Front in the treatment of atrial fibrillation

CryoCath receives CE mark to sell Arctic Front® in European Union

CryoCath receives Regulatory approval to market Freezor® and Arctic Circler® in China

CryoCath’s Freezor® MAX obtains FDA approval in the U.S.

CryoCath & ATS Medical enter exclusive global partnership

CryoCath announces exciting start in atrial fibrillation study with Arctic Circler™ Balloon (renamed Arctic Front®)

CryoCath’s FrostByte™ receives FDA clearance, company poised to launch

CryoCath’s SurgiFrost® achieves over 90% success rates in treating atrial fibrillation

Freezor® approved by FDA

CryoCath receives CE Mark for Freezor® MAX

CryoCath acquires permanent global rights to develop, manufacture and market SurgiFrost® world-wide

Freezor® Xtra receives 510(k) number from the FDA: K030303

Freezor® receives commercial approval in Canada

SurgiFrost® first used commercially in the U.S.

FDA formally accepts PMA application for Freezor®

First successful use of CryoAblation in pediatric patient using Freezor®

CryoCath receives CE mark to sell Freezor® Xtra and Arctic Circler® in the European Union

Japan Lifeline selected as distributor for important Japanese market

CryoTherapy used successfully in clinical trials on angiogenic revascularization

Freezor® CryoAblation System launched in Europe

Strategic alliance formed to develop and market our surgical cryoprobe, SurgiFrost®

U.S. FDA approval of our PMA filing plan for Freezor®

Freezor® used to treat some 700 patients in more than 30 European centers

Arctic Circler® catheter used to treat Atrial Fibrillation in first human patient

CryoCath reaches 100 employees

CryoCath receives European regulatory approval to commercialize Freezor®, our first-generation CryoTherapy product

CryoCath becomes a public company with the largest ever Canadian IPO in Biotech

CryoCath acquires core patent outright as well as rights to 6 other U.S.-issued patents for associated methods and designs

CryoCath treats first patient

CryoCath incorporates and establishes headquarters in Montreal, Canada

Patent issued for flexible, steerable catheter delivering cryoenergy within the cardiovascular system

Dr. Peter Friedman of Brigham & Women's University Hospital, Harvard University develops the core technology of our CryoTherapy platform